ORIC Pharmaceuticals Announces Late-Breaking Oral Presentations on Enozertinib (ORIC-114) at ESMO Asia Congress 2025

ORIC Pharmaceuticals announced two oral presentations on enozertinib data at ESMO Asia Congress 2025, focusing on NSCLC treatments.

Quiver AI Summary

ORIC Pharmaceuticals, Inc. has announced two significant oral presentations regarding their drug enozertinib (ORIC-114) at the upcoming ESMO Asia Congress 2025 in Singapore. The mini-oral presentation will cover results from a Phase 1b trial involving previously treated patients with EGFR atypical mutant non-small cell lung cancer (NSCLC), while the proffered paper presentation will focus on data from both treated and treatment-naïve patients with EGFR exon 20 mutant NSCLC. The company will also hold a conference call and webcast on December 6, 2025, to discuss these findings further. ORIC Pharmaceuticals is dedicated to developing treatments for cancer by addressing therapeutic resistance, with enozertinib targeting specific genetic mutations associated with various cancers.

Potential Positives

Announcement of late-breaking presentations at the ESMO Asia Congress 2025 underscores ORIC Pharmaceuticals' leading role in advancing innovative cancer treatments.
Data to be presented on enozertinib (ORIC-114) in previously treated and treatment-naïve patients highlights the potential of the drug in addressing specific oncological needs.
The company’s participation in a significant international conference enhances its visibility and credibility within the oncology community.
The planned conference call and webcast allow for engagement with investors and stakeholders, fostering transparency and communication about the company's developments.

Potential Negatives

The press release focuses solely on upcoming presentations, which may indicate a lack of significant recent developments or breakthroughs in their therapies.
There is no mention of positive results or findings from the Phase 1b trial, which could raise concerns about the efficacy of enozertinib (ORIC-114).
The company does not provide any data or context about the current status of other clinical candidates outside of ORIC-114, potentially highlighting a narrow focus that may be risky for investors.

FAQ

What presentations will ORIC Pharmaceuticals give at ESMO Asia Congress 2025?

ORIC will present two oral presentations on enozertinib data from a Phase 1b trial, focusing on EGFR mutations in NSCLC.

When are the presentations scheduled during the congress?

The mini-oral presentation is on December 5, 2025, and the proffered paper presentation is on December 6, 2025.

How can I access the full abstracts from the presentations?

Full late-breaking abstracts are available for public viewing on the ESMO Asia Congress website.

What is ORIC Pharmaceuticals' focus?

ORIC Pharmaceuticals focuses on developing treatments to address mechanisms of therapeutic resistance in cancer.

How can I join ORIC's conference call and webcast?

To join the conference call on December 6, 2025, pre-register online to receive the necessary phone number and passcode.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ORIC Insider Trading Activity

$ORIC insiders have traded $ORIC stock on the open market 16 times in the past 6 months. Of those trades, 2 have been purchases and 14 have been sales.

Here’s a breakdown of recent trading of $ORIC stock by insiders over the last 6 months:

JACOB CHACKO (PRESIDENT AND CEO) has made 0 purchases and 4 sales selling 250,000 shares for an estimated $2,865,011.
DOMINIC PISCITELLI (Chief Financial Officer) has made 0 purchases and 10 sales selling 51,000 shares for an estimated $576,140.
ANGIE YOU has made 2 purchases buying 28,000 shares for an estimated $262,898 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ORIC Hedge Fund Activity

We have seen 88 institutional investors add shares of $ORIC stock to their portfolio, and 79 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ECOR1 CAPITAL, LLC added 5,110,048 shares (+315.8%) to their portfolio in Q3 2025, for an estimated $61,320,576
ORBIMED ADVISORS LLC added 2,742,475 shares (+305.0%) to their portfolio in Q3 2025, for an estimated $32,909,700
BOXER CAPITAL MANAGEMENT, LLC removed 1,732,571 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $17,585,595
VANGUARD GROUP INC added 1,525,445 shares (+48.8%) to their portfolio in Q3 2025, for an estimated $18,305,340
ROYCE & ASSOCIATES LP added 1,223,709 shares (+521.2%) to their portfolio in Q3 2025, for an estimated $14,684,508
BLACKROCK, INC. added 1,198,635 shares (+29.4%) to their portfolio in Q3 2025, for an estimated $14,383,620
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,065,334 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $12,784,008

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ORIC Analyst Ratings

Wall Street analysts have issued reports on $ORIC in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Evercore ISI Group issued a "Outperform" rating on 11/20/2025
JP Morgan issued a "Overweight" rating on 11/18/2025
Citigroup issued a "Buy" rating on 11/17/2025
Oppenheimer issued a "Outperform" rating on 11/14/2025
Wells Fargo issued a "Overweight" rating on 11/14/2025
HC Wainwright & Co. issued a "Buy" rating on 11/14/2025
Ladenburg Thalmann issued a "Buy" rating on 07/08/2025

To track analyst ratings and price targets for $ORIC, check out Quiver Quantitative's $ORIC forecast page.

$ORIC Price Targets

Multiple analysts have issued price targets for $ORIC recently. We have seen 9 analysts offer price targets for $ORIC in the last 6 months, with a median target of $18.0.

Here are some recent targets:

Cory Kasimov from Evercore ISI Group set a target price of $25.0 on 11/20/2025
Anupam Rama from JP Morgan set a target price of $20.0 on 11/18/2025
Yigal Nochomovitz from Citigroup set a target price of $16.0 on 11/17/2025
Robert Burns from HC Wainwright & Co. set a target price of $23.0 on 11/14/2025
Matthew Biegler from Oppenheimer set a target price of $15.0 on 11/14/2025
Derek Archila from Wells Fargo set a target price of $19.0 on 11/14/2025
Brad Canino from Guggenheim set a target price of $18.0 on 09/04/2025

Full Release

SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-naïve patients with EGFR exon 20 mutant NCSLC.

Mini-oral presentation details:

Title:	Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Previously Treated NSCLC with EGFR Atypical Mutations: Randomized Dose Optimization and CNS Activity
Presentation Number:	LBA15
Session Type and Title:	Mini Oral session 1: Thoracic malignancies
Lecture Date and Time:	Friday, December 5, 2025; 11:38 – 11:43 a.m. SGT

Proffered paper oral presentation details:

Title:	Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in EGFR Exon 20 Mutant NSCLC: Randomized Dose Optimization and CNS Activity
Presentation Number:	LBA13
Session Type and Title:	Proffered Paper session: Thoracic malignancies
Lecture Date and Time:	Saturday, December 6, 2025; 10:02 – 10:12 a.m. SGT

Full late-breaking abstracts are available for public viewing via the ESMO Asia Congress website .

Conference Call and Webcast Details
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com . The webcast will be available for replay for 90 days following the presentation.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer . ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com , and follow us on X or LinkedIn .

Contact:

Dominic Piscitelli, Chief Financial Officer
[email protected]
[email protected]